Sign in to fuzzto save your conversations, follow your research and come back anytime.
Aarti Pharma Labs
AARTIPHARM
NSE
BSE
NSEBSESectorHealthcare
868.10
Loading chart…
NSEBSEThe Quarter story
The two most recent quarterly results, compared side-by-side.
Aarti Pharmalabs delivers strong profit recovery and top-line growth in Q1 FY27, driven by Xanthine derivatives and regulated market expansion, though export softness and rising costs warrant monitoring.
Consolidated operational revenue grows from ₹3,862 Cr to ₹5,358 Cr from Q1 FY26 to Q1 FY27, driving strong top-line momentum.
International sales share falls from 56% to 48% from Q1 FY26 to Q1 FY27, indicating export softness.
Xanthine derivatives revenue share rebounds from 49.6% to 57% from Q1 FY26 to Q1 FY27, highlighting segment resurgence.
Operating expenses rise from ₹2,801 Cr to ₹4,032 Cr from Q1 FY26 to Q1 FY27, signaling cost inflation pressure.
Regulated market share expands from 49% to 58% from Q1 FY26 to Q1 FY27, confirming premium market penetration.
API & Intermediates revenue share declines from 40.8% to 30% from Q1 FY26 to Q1 FY27, reflecting portfolio mix dilution.
Profit after tax surges from ₹495 Cr to ₹761 Cr from Q1 FY26 to Q1 FY27, confirming bottom-line expansion.
Average trading volume drops from 496.56 to 267.71 from Q1 FY26 to Q1 FY27, warning of liquidity drain.
Joint venture contribution turns positive, growing from a loss of ₹18 Cr to a gain of ₹74 Cr from Q1 FY26 to Q1 FY27, indicating successful partnership turnaround.
Depreciation and amortization increases from ₹228 Cr to ₹300 Cr from Q1 FY26 to Q1 FY27, signaling heavy capex depreciation burden.